Eli Lilly and Company (LLY)

NYSE: LLY · IEX Real-Time Price · USD
769.54
-0.10 (-0.01%)
At close: Feb 23, 2024, 4:00 PM
768.75
-0.79 (-0.10%)
After-hours: Feb 23, 2024, 7:59 PM EST

Company Description

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.

In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache.

Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.

It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company
Eli Lilly and Company logo
Country United States
Founded 1876
Industry Drug Manufacturers - General
Sector Healthcare
Employees 43,000
CEO David A. Ricks

Contact Details

Address:
Lilly Corporate Ctr, Drop Code 1094
Indianapolis, Indiana 46285
United States
Phone (317) 276-2000
Website lilly.com

Stock Details

Ticker Symbol LLY
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000059478
CUSIP Number 532457108
ISIN Number CNE000000H95
Employer ID 35-0470950
SIC Code 2834

Key Executives

Name Position
David A. Ricks Chairman, Chief Executive Officer and President
Anat Ashkenazi Executive Vice President and Chief Financial Officer
Dr. Daniel M. Skovronsky M.D., Ph.D. EVice President, Chief Scientific Officer and President of Lilly Research Laboratories and Lilly immunology
Anat Hakim J.D. Executive Vice President, General Counsel and Secretary
Patrik Jonsson EVice President, Chief Customer Officer, President of Lilly Diabetes and Obesity and President Lilly USA
Donald A. Zakrowski Chief Accounting Officer and Vice President of Finance
Diogo Rau Executive Vice President and Chief Information and Digital Officer
Alonzo Weems Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
Eric Dozier Executive Vice President of Human Resources and Diversity
Jeffrey N. Simmons Senior Vice President and President of Elanco Animal Health

Latest SEC Filings

Date Type Title
Feb 21, 2024 10-K Annual Report
Feb 15, 2024 144 Filing
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 8-K Current Report
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024 424B2 Prospectus
Feb 8, 2024 144 Filing
Feb 7, 2024 FWP Free Writing Prospectus
Feb 7, 2024 424B2 Prospectus
Feb 6, 2024 8-K Current Report